STOCKS TELEGRAPH

Tag: INMB

  • INmune Bio, Inc. (INMB) Stock on the Rise Following First Patient Treatment in INKmune Phase 1 Clinical Trial

    INmune Bio, Inc. (INMB) stock prices were up by 12.67% as of the market closing on July 13th, 2021, bringing the price per share up to USD$26.68. Subsequent premarket fluctuations saw the stock rise by 7.01%, bringing it up to USD$28.55.

    INKmune

    July 12th, 2021 saw the company announce the use of INKmune, its Natural Killer (NK) cell priming platform, had been used to treat the first patient in Phase 1 clinical trial. The treatment is being explored as a viable option for patients with high-risk myelodysplastic syndrome. MDS is a hematopoietic stem cell disorder that is indicated by functionally defective NK cells, with the level of dysfunction being predictive of overall survival. Roughly 33% of MDS cases develop into acute myelogenous leukemia (AML). With no known cure for MDS, existing therapies like chemotherapy and bone marrow/stem cell transplantation have varying degrees of success.

    Research Conducted

    With levels of NK function in MDS patients being predictive of overall survival, 15 years of lab research into potential patient treatment has raised hopes. The enhancement of low-level NK activity in patients with poor prognosis to the level of those with better overall survival, thereby altering the course of the disease, could be highly commercially promising.

    Scope of Research

    Lab work has shown INKmune binding to multiple NK receptors and initiates the activation of more than 3000 genes associated with function, trafficking, proliferation, and overall survival. With not a single cytokine available that has such a myriad of physiological effects, INKmune is being referred to as a psuedokine.

    Expanded Opportunities

    The treatment of the first patient in the trial serves as a major milestone, with the company being the first to study the INKmune platform in a formal clinical setting. With it being widely known that dysfunctional NK cells in cancer patients are not effective at eradicating residual disease after chemotherapy, leading to relapse and poor outcomes. The company has shown that with the delivery of tumor-specific activating signals to NK cells with INKmune, autologous tumor killing can be initiated.

    Future Outlook for INMB

    Armed with the significant milestone of having treated the first patient in the study, INMB is poised to capitalize on the opportunities afforded to it as a result. The company is keen to push for the accelerated development and eventual commercialization and proliferation of the treatment. Current and potential investors are hopefully that management will continue to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • Pre Market Report: Stock Watch Ahead Of U.S Markets Opening

    Pre Market Report: Stock Watch Ahead Of U.S Markets Opening

    U.S markets are showing signs of a rebound after a weak showing in Monday’s session. Nonetheless, market sentiment remains mixed. On the downside, there are fears that the economy could be headed for another shutdown as the coronavirus numbers continue to rise. States like California are slowing down on reopening to curtail the virus spread. There are also concerns about equities being overpriced. Most companies have taken a hit in their revenues, yet the stock market has rallied back to pre-crisis levels. This indicates a disconnect between stock market valuations and corporate performance. On the positive side, the U.S government appears ready to keep supporting the economy. Today, The New York Times has reported that the Trump administration is calling for a payroll tax cut, relief for distressed industries, and a tax holiday on capital gains. The New York Times further states that the next stimulus could be between $1 trillion to $3 trillion. While this adds to the already ballooning deficit, it offers critical support to the economy, and more specifically the equity markets.  In spite of the mixed outlook, there are stocks that are on a roll pre-market and could perform well in the day. Some of them are as below.

    Tesla [NASDAQ: TLSA]

    Tesla continues its stellar performance and is up by over 6% pre-market. The stock has been on an exponential growth path driven by its sales numbers, and a growing appetite for stocks in the market. Tesla recently announced that in Q2, it had delivered 90,650 units, beating its estimates of 74,130 units.  Some analysts believe that this points to growing demand for the company’s vehicles, which is playing to support its stock price. A JP Morgan recently stated that Tesla was now set to break even on GAAP in Q2, a factor that is changing the market’s risk evaluation of the stock. With such optimism at play, TLSA could continue its rally if the market opens in positive territory.

    INmune Bio Inc [NASDAQ: INMB]

    INmune Bio is another big mover pre-market and is up by 142.82% at the time of writing. The rally comes hours after the company released interim data showing that its treatment called XPro1595 reduces neuroinflammation in people suffering from Alzheimer’s disease. XPro1595 is an inhibitor for tumor necrosis factor that neutralizes soluble TNF, and with implications on the pathology of Alzheimer’s. Commenting on the results, the company’s director of neuroscience, CJ Barnum stated that they were happy with the findings. The response the stock has received pre-market shows that investors are optimistic that this could be a major breakthrough not just for Alzheimer’s patients, but also for the company’s bottom-line.

    ElectroCore Inc [NADAQ: ECOR]

    ElectroCore was a top gainer in yesterday’s session and closed with gains of 109.41%. The stock seems poised to continue this rally and is up by 6% in pre-market trading. The upside momentum is driven by the company’s announcement that it had received emergency use authorization from the FDA for its COVID-19 treatment.  The company stated that it was now working on making its new therapy available to medics treating COVID-19 patients that have asthma and other breathing difficulties,